Emisphere Technologies, Inc. (EMIS)
|Net Income (ttm)||-2.15M|
|Trading Day||Dec 9, 2021|
|Day's Range||7.81 - 7.81|
|52-Week Range||4.06 - 1046|
There are no news available yet.
Emisphere Technologies operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and ... [Read more...]
Drug Manufacturers-Specialty & Generic
|Stock Exchange |
|Ticker Symbol |
In 2016, EMIS's revenue was $1.20 million, an increase of 190.75% compared to the previous year's $411,000. Losses were -$10.04 million, -75.13% less than in 2015.